Home > Articles > The GIP receptor explained: why incretin research targets it
Prepared by: Research Desk
Prepared by: Research Desk. Sources are linked for verification.
The GIP receptor is one of three hormone receptors that the investigational drug retatrutide is designed to activate. It is also the least intuitive of the three. For years, researchers disagreed about whether this receptor should be switched on or switched off in obesity research. This explainer covers four things: what the receptor is, where it sits in the body, what the published research says about the agonist-versus-antagonist debate, and why the receptor now appears in dual and triple agonist programs. It is a background page. For trial-by-trial results, see our retatrutide guide.
Status note: As of the May 2026 pipeline update, retatrutide was investigational and not FDA-approved, with an FDA decision listed as a 2027 event [11]. The FDA states that retatrutide has "not been found safe and effective for any condition" [12]. For the regulatory record and the filing timeline, see our approval status page.
What GIP is
GIP stands for glucose-dependent insulinotropic polypeptide. It is a gut hormone released from cells in the upper small intestine after eating. Together with GLP-1, it is one of the two classic "incretin" hormones. Incretins enhance insulin release when blood glucose is raised, and they contribute less when glucose is normal. The "glucose-dependent" in the name refers to that dependence on blood glucose.
A 2025 review in Molecular Metabolism summarises decades of GIP biology, from its discovery to its current place in drug research [1]. The review covers the hormone's effects on insulin and glucagon secretion, its activity in fat tissue and bone, and its signalling in the brain.
What the GIP receptor is and where it is found
The GIP receptor (often abbreviated GIPR) is a G protein-coupled receptor on the cell surface. It belongs to the same receptor family as the GLP-1 and glucagon receptors. When GIP binds, the receptor triggers signalling inside the cell, mainly through the second messenger cyclic AMP [1].
The receptor is not confined to one organ. Published research describes GIPR expression in:
Pancreatic islets, where it is linked to insulin and glucagon secretion [1].
Adipose (fat) tissue, where GIP signalling has been studied in relation to how fat is stored and handled [1].
The brain, including the hypothalamus, a region involved in regulating food intake [2].
Cardiovascular tissues, reviewed separately in the journal Peptides [4].
This wide distribution is one reason the receptor is hard to study. The same signal can have different effects in different tissues. Results from one tissue or one species do not automatically carry over to another.
The central puzzle: activate it or block it?
The GIP receptor has been the subject of an unusually long scientific debate. Fittingly, a 2025 review article in Diabetes is titled "Therapeutic Targeting of the GIP Receptor-Revisiting the Controversies" [3]. The disagreement has two sides.
The case that was made for blocking it
Earlier lines of research pointed toward blocking GIP signalling. The 2025 review recounts animal studies in which mice lacking a functional GIP receptor gained less weight on high-fat diets [3]. Researchers also observed that GIP's insulin-releasing effect appears blunted in type 2 diabetes [1][3]. These observations led some groups to pursue GIP receptor antagonists as an obesity research strategy. Antagonists are molecules that block the receptor.
The case that was made for activating it
Other evidence points the opposite way. A 2019 mouse study in Cell Metabolism identified GIP receptor-expressing cells in the hypothalamus. It reported that activating these cells reduced food intake [2]. That finding suggested how stimulating the receptor could influence eating behaviour through the brain, not only through insulin secretion.
The development of combined GIP and GLP-1 receptor agonists added further weight to the activation side. A 2024 review in Frontiers in Endocrinology describes the mechanisms of GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists. It sets out how the two pathways are thought to interact [6].
How both observations might fit together
One idea discussed in the review literature is that long-term exposure to a receptor agonist can make the receptor less responsive over time, through desensitisation or internalisation. If so, sustained "activation" could partly resemble "blocking" in its downstream effects. That could help explain why both strategies have produced interesting results in animal studies. The 2025 review presents this as a question still being worked out, not a settled conclusion [3].
How the GIP receptor entered dual and triple agonist research
Dual agonists and "imbalanced" activity
A 2020 pharmacology study in JCI Insight characterised tirzepatide, a dual GIP and GLP-1 receptor agonist, as "imbalanced and biased" [5]. The study reported that the molecule behaved much like native GIP at the GIP receptor. At the GLP-1 receptor, it showed relatively less activity. Its signalling there also favoured some intracellular pathways over others.
This was laboratory work using cell-based assays. Its relevance is that "dual agonist" does not mean equal activity at both receptors. The balance between receptors is a design choice that researchers measure and report.
Triple agonists add glucagon
Retatrutide extends the concept by adding glucagon receptor activity to GIP and GLP-1 receptor activity. Its phase 2 program included two published trials:
A trial in adults with obesity, published in the New England Journal of Medicine in 2023 [7].
A trial in people with type 2 diabetes, published in The Lancet the same year [8].
A phase 3 trial in adults with obesity and type 2 diabetes (TRIUMPH-2) followed in The Lancet in 2026 [10].
These trials report outcomes for the molecule as a whole. They are not designed to separate how much any single receptor contributes. That limitation matters when reading claims about "what GIP does" in a combination drug, because the results describe the combination rather than the individual receptor.
Body composition questions
Another active research question is how incretin-based drugs affect the split between fat mass and lean mass. A 2025 systematic review and network meta-analysis in Metabolism pooled randomised trial data on body composition for GLP-1 receptor agonists and co-agonists [9]. Work like this compares drug classes rather than isolating the GIP receptor. It forms part of the wider context in which GIP-containing molecules are evaluated.
The cardiovascular angle
GIP receptors are found in heart and blood vessel tissue, so researchers have asked what GIP signalling does in the cardiovascular system. A 2020 review in Peptides collected the available evidence on GIP receptor biology in cardiovascular tissues [4]. Much of that evidence comes from cell and animal studies. The review works mainly as a map of open questions, not as a source of firm conclusions about humans.
Reading GIP receptor research carefully
A few points help keep claims in proportion:
Species matters. Several key GIP receptor findings come from mouse studies [2][3]. Receptor distribution and responses can differ between mice and humans.
Tissue matters. The same receptor can have different roles in pancreas, fat, brain and blood vessels [1][4].
Combination drugs blur attribution. Trials of multi-receptor agonists measure the combined molecule [7][8][10].
Pharmacology is not outcome. Cell-based receptor studies describe how a molecule binds and signals [5]. On their own, they do not describe what happens in people.
Further reading: choosing an endocrinology book
Readers who want to go deeper than a single explainer often turn to textbooks or general-audience science books on hormones and metabolism. The field moves quickly, so it pays to compare titles on a few neutral criteria before buying:
Edition and publication date. Hormone receptor research has shifted substantially in recent years. A recent edition is more likely to reflect current thinking.
Referencing. Books that cite primary studies make it possible to check claims against the original research.
Scope and level. Some books focus on physiology, others on pharmacology, and others are written for general readers. Check the table of contents and sample pages.
Author background. Look for authors with a research record in endocrinology or metabolism.
Format and price transparency. Compare print and ebook pricing, and check whether the listed price includes shipping.
Bookseller listings and publisher descriptions usually show the edition, page count and table of contents. Checking these is a quick way to confirm whether a title matches the depth wanted.
Libraries are another option. Many offer interlibrary loans for academic texts, which is a low-cost way to sample a book before purchase.
Frequently asked questions
What does GIP stand for?
GIP stands for glucose-dependent insulinotropic polypeptide. It is a gut hormone that, together with GLP-1, makes up the two classic incretin hormones. Incretins enhance insulin release when blood glucose is raised [1].
Why did researchers argue about activating versus blocking the GIP receptor?
Some animal studies suggested that removing GIP receptor signalling limited weight gain on high-fat diets, which pointed toward blocking. Other studies pointed toward activation, including mouse work on hypothalamic GIP receptor cells. A 2025 review discusses how both observations might be reconciled [2][3].
Does retatrutide research show what the GIP receptor does on its own?
No. Retatrutide trials measure the effects of a single molecule that acts on three receptors. They are not designed to separate the contribution of the GIP receptor from the GLP-1 and glucagon receptors [7][8][10].
For how we source and label evidence on this site, see About TripleReta.
Last updated: 19 October 2026.
Related on this site
Is retatrutide FDA approved? Legal status and approval timeline
Retatrutide: mechanism, trial findings and side effects explained
How to read retatrutide trial results: endpoints, placebo, dropouts
Books about clinical trials: a reading list for following research
Retatrutide vs tirzepatide: how the trial designs and data compare
Retatrutide mechanism of action: one molecule, three receptors
Not medical advice. This page reports published research and regulatory records for information only.
Research-only notice: Content on this site is provided for research and educational purposes only and is not intended for human use. It is not medical advice.
Translation notice: Some content on this site may have been machine-translated using Google Translate and may contain errors.